In this agreement, Syntopix will make available the company’s library of compounds for evaluation of their application in a number of areas as candidates for development into commercial products.
The financial details of the agreement are confidential, although Syntopix will receive an upfront payment at the start of the exclusivity period and further payments for any compounds subject to additional evaluation. Commercialization of a compound would be subject to a licensing agreement to be negotiated separately.
Stephen Jones, CEO of Syntopix, said: “I am delighted that Syntopix has entered into this agreement with one of the world’s largest consumer healthcare companies. We continue to identify potential markets for to the antimicrobial expertise of Syntopix, and we believe that our technology has the potential to improve the effectiveness of many healthcare brands.
“Our core focus remains the development of products for the topical treatment of dermatological diseases, though this agreement further highlights our ability to leverage our assets into consumer healthcare.”